THE EFFECT OF TREATMENT WITH MIFEPRISTONE ON THE QUALITY OF LIFE OF PATIENTS WITH UTERINE MYOMA

Purpose of the study: evaluation of the quality of life of patients with symptomatic uterine myoma up to 12 weeks of gestation against a background of mifepristone 50 mg daily continuously for 3 months.

Material and methods. The prospective study involved 141 patients with uterine myoma who received treatment with mifepristone (Gynestril®) 50 mg continuously for 3 months. In order to evaluate changes in the volume of uterine bleeding, each patient kept a diary where she registered the number of sanitary napkins used. Sonographic examination was used to evaluate the size of the uterus and fibroids. The Visual Analogue Scale (10-point VAS scale) was used to assess the pain intensity. Quality of life of patients and their satisfaction with the therapy was also evaluated by a 10-point VAS scale. The complaints, physical examination data and results of sonographic studies were recorded before and immediately after the end of treatment (1st and 2nd visits).

Study results. Drug therapy with Gynestril® (mifepristone 50 mg) for patients with uterine myoma for 3 months helped to obtain a statistically significant (p < 0.001) improvement across all the evaluated parameters: in a large majority of patients, control of menstrual blood loss was achieved (decreased duration and volume of bleeding), while 85 patients (60.3%) achieved reversible drug-induced amenorrhea, and 43 patients (30.5%) - oligomenorrhea; a large majority of patients achieved reduction of pain severity according to VAS, while in 118 (83.7%) patients the parameter was estimated as “slight pain/no pain” after the end of treatment. According to the ultrasound results, a statistically significant decrease was achieved in the number of displayable fibroids (from 2.1 to 1.9 at an average), the volume of the dominant myoma node (on average by 65% from 37.34 to 13.27 cm3) and of the uterus (an average of 35% from 182.71 to 118.09 cm3). In addition, a vast majority of patients - 99.9% - evaluated the quality of life and satisfaction with treatment as high.

Conclusions. Therefore, the results of the study demonstrate that Gynestril® is highly effective, safe and promising in the pharmaceutical treatment of uterine fibroids. 

1. Леваков С.А., Гуриев Т.Д., Шешукова Н.А. и др. Миома матки. Учебное пособие. М., 2015. 62 с.

2. Миома матки: диагностика, лечение, реабилитация. Клинические рекомендации (протокол лечения). М., 2016.

3. Волков В.Г., Гусева Н.В., Горшкова И.А. Оптимизация консервативного лечения миомы матки антипрогестеронами и оценка влияния проводимой терапии на качество жизни женщин. Вестник новых медицинских технологий, 2011, ХVIII(1): 93.

4. Самойлова Т.Е., Аль-Сейкал Т.С. Перспективы применения мифепристона в лечении гормонально-зависимых заболеваний у женщин (обзор литературы). Проблемы репродукции, 2004, 6: 35-42.

5. Фаткуллин И.Ф., Баканова А.Р. Эффективность адъювантной терапии после консервативной миомэктомии у пациенток репродуктивного возраста. Приложение к «Доктор.Ру», 2011, 9(68): 6-10.

6. Wiener JJ, Newcombe RG. Measurements of uterine volume: A comparison between measurements by ultrasonography and by water displacement. J Clin Ultrasound, 1992, 20: 457-460; Вихляева Е.М. Лейомиомы

7. матки: Руководство по диагностике и лечению. М., 2004. С.164.

8. Brunn J, Block U, Ruf G et al. Volumetrie der Schilddrüsenlappen mittels Real-time-Sonogrpahie. Dtsch Med Wochenschr, 1981, 106: 1338-1340.

9. Živković N, Živković K, Despot A, Paić J, Zelić A. Measuring the volume of uterine fibroids using 2- and 3-dimensional ultrasound and comparison with histopathology. Acta Clin Croat, 2012, 51: 579-589.